Navigation Links
Johns Hopkins researchers suppress 'hunger hormone'
Date:9/15/2008

upplying blood to the stomachs. There, they administered one-time injections of saline in the left gastric arteries of five control pigs, and in the other five, one-time injections of sodium morrhuate, a chemical that destroys the blood vessels.

The team then sampled the pigs' blood for one month to monitor ghrelin values. The levels of the hormone in GACE-treated pigs were suppressed up to 60 percent from baseline.

"Appetite is complicated because it involves both the mind and body," Arepally says. "Ghrelin fluctuates throughout the day, responding to all kinds of emotional and physiological scenarios. But even if the brain says "produce more ghrelin," GACE physically prevents the stomach from making the hunger hormone."


'/>"/>

Contact: Maryalice Yakutchik
myakutc1@jhmi.edu
443-287-2251
Johns Hopkins Medical Institutions
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Johnson & Johnson to Participate in Bear Stearns 20th Annual Healthcare Conference
2. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
3. Johnson & Johnson Campaign for Nursings Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program
4. Johns Hopkins receives $100 million grant to speed research from clinic to community
5. Trust for Americas Health Receives $7.6 Million Grant from the Robert Wood Johnson Foundation to Advance the Quality and Impact of the Public Health System
6. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
7. Johnson & Johnson Tops Annual Pharmaceutical Company Rankings in a New Report From Industry-Leading Publication Scrip
8. Independence Technology, A Johnson & Johnson Company, Renews Its Contract With Creative Technology Services
9. In Johnstown Governor Rendell Launches Tour to Insure; Urges Passage of Plan to Give Access to Affordable Health Insurance
10. Johnson & Johnson Launches Global Diabetes Institute to Provide State-of-The- Art Education, Training to Health Professionals
11. Robert Wood Johnson Foundation Announces $15.6 Million Grant to Apply Power of the Archimedes Model to Critical Health Care Decisions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2009)...a., July 2 Acetaminophe...and prescription medicines to help relieve pain an...n by a brand name, Tylenol and prescription brand ...ommittee for the FDA met on June 30, 2009 to addre...inophen. The committee voted 20-17 to urge the FD...
(Date:7/2/2009)...ne of 63 businesses honored in Washington, D.C. ,...ire/ -- Texas Health Resources has received the ... the National Business Group on Health. , , (Lo...2/DC41773LOGO ) , , The award recognizes the...rams that promote a healthy workplace and for help...
(Date:7/2/2009)...ght problems faced by youngsters with the disease ... Children with type 1 diabetes are more likely to ...easing their risk of serious health complications,... study that explored the weight problems faced by ...n form of the disease that usually shows up in chi...
(Date:7/2/2009)...cal and biological issues need to be addressed in ...y detection of cancer, according to a commentary p...onal Cancer Institute . , The biomarker pipeline...cludes the identification of promising biomarkers ...tive evaluation of biomarkers for cancer screening...
Breaking Medicine News(10 mins):Health News:Viles & Beckman, LLC: Stop Your Headache NOT Your Liver 2Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 2Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 3Health News:Kids With Type 1 Diabetes Often Overweight 2
...ir Cell culture small pox vaccine// (CCSV) derived.... Small pox vaccine currently used is a live, atte... vaccine produces adverse effects in vaccinated, 1...reactions of every million. 1 to 2 people every mi...
... problem of super bugs to the extensive// use of a...gs are a new kind of microorganisms, mainly bacter...range of antibiotics. The researchers of Fogarty I...ers who together had published the research report...
...porosis is useful, but changes in bone// mineral d...ain treatment options are anti-resorptive agents t...ious fractures, treatment with an anabolic agent t...ble, and this is now possible since the introducti...
...Journal of Neurosurgery suggests that Clazosentan ...constriction of blood vessels (called vasospasm) f.... Normally constriction of blood vessels occurs ...this leads to strokes and neurological deficits. T...
Other Medicine News:Health News:The Benefits of Strontium in the treatment for Osteoporosis Questioned 2Health News:Clazosentan May help to Improve Blood Circulation after Brain Hemorrhage due to burst Aneurysm 2
(Date:6/30/2009)...tCall/ -- Cephalon, Inc. (Nasdaq: CEPH ) today a...Drug Application (sNDA) to the U.S. Food and Drug ...L(R) (armodafinil) Tablets [C-IV] for the indicati...ive sleepiness associated with jet lag disorder re...s an acute condition that occurs when a person,s i...
(Date:6/29/2009)...ents achieved primary and secondary endpoints , ...celRx Pharmaceuticals, Inc. today announced positi...evaluating the safety and efficacy of its ARX-01 S... post-operative pain in patients requiring opioid ...ebo, patients receiving ARX-01 Sufentanil NanoTabs...
(Date:6/28/2009)...ne 29 , - Study Triggers $7...roup Corporation ("Sosei"; TSE Mothers Index: 4565...ounce the commencement of a Phase III,clinical st...cting muscarinic,antagonist (LAMA) for the treatm...D). NVA237 is a dry powder formulation for oral in...
(Date:6/26/2009)...of New Anti-TNF Therapy in Three Rheumatic Disease...SHAM, Pa. and KENILWORTH, N.J., June 26 /PRNewswir...hering-Plough Corporation (NYSE: SGP ) announced...or Human Use (CHMP) of the European Medicines Agen...the approval of SIMPONI(TM) (golimumab) as a once-...
Breaking Medicine Technology:Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder 2Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder 3Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder 4AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 2AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 3AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 4Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 9SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 10New type of vaccines deliver stronger and faster immune response 6002 1New type of vaccines deliver stronger and faster immune response 6002 2Global warming is changing organic matter in soil 6000 1Global warming is changing organic matter in soil 6000 2Ants may help researchers unlock mysteries of human aging process 5998 1Ants may help researchers unlock mysteries of human aging process 5998 2Ants may help researchers unlock mysteries of human aging process 5998 3Brooks Kushman Stomps on Multiple Sclerosis 3A Local Law Firm Honored by Multiple Sclerosis Society for Fundraising Efforts 30466 1Brooks Kushman Stomps on Multiple Sclerosis 3A Local Law Firm Honored by Multiple Sclerosis Society for Fundraising Efforts 30466 2
...ial growth system, combines orbital shaking, oxyge...or bacterial growth. It is designed for easy integ... Extractor. The uniquely engineered HT-MegaGrowTM ...hakers. Plate-holding cassettes allow for high pla...
Inquire
Inquire
Inquire
Medicine Products: